These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2870608)

  • 21. [Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms].
    Lejoyeux M; Gorwood P; Stalla-Bourdillon A; Adès J
    Encephale; 1993; 19(1):17-21. PubMed ID: 8275889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experiences in an open and a double-blind trial.
    Pöldinger W
    Acta Psychiatr Belg; 1978; 78(1):96-101. PubMed ID: 347884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
    Roncoroni D
    Psychiatr Prax; 1984 Mar; 11(2):56-8. PubMed ID: 6144121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The response of untreated chronic schizophrenics to haloperidol and haloperidol decanoate.
    Leff JP; Tress KH
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():27-40. PubMed ID: 3559160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bromperidol maintenance in schizophrenia.
    McEvoy JP; Wilson WH; Ban TA; Brannen JO; Berney S
    Pharmacopsychiatria; 1982 May; 15(3):95-6. PubMed ID: 7100263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial with bromperidol in psychotic states.
    Brasseur R
    Acta Psychiatr Belg; 1978; 78(1):110-7. PubMed ID: 645404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary note on the antipsychotic efficacy of bromperidol.
    Bataille M
    Acta Psychiatr Belg; 1978; 78(1):173-9. PubMed ID: 347879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
    Gelders YG
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-11. PubMed ID: 3559159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The characteristics of side-effects of bromperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Ishida M; Tanaka O; Mihara K; Kaneko S; Otani K
    Psychiatry Clin Neurosci; 2002 Feb; 56(1):103-6. PubMed ID: 11929578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
    Kane JM
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC; Kennedy NM; Gribbon D
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
    Yasui-Furukori N; Saito M; Nakagami T; Kaneda A; Tateishi T; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):286-91. PubMed ID: 16386826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients].
    Bralet MC; Yon V; Loas G; Noisette C
    Encephale; 2000; 26(6):32-41. PubMed ID: 11217537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
    Lemperiere T; Ropert R; Leger JM; Alexandre JY; Clerc G; Darondel A; Delaunay J; Delteil P; Malauzat D; Raynaud J
    Encephale; 1984; 10(5):217-22. PubMed ID: 6519017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
    Abuzzahab FS; Zimmerman RL
    J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of the efficacy of haloperidol decanoate].
    Alvarez JV; Li Gambi M
    Acta Psiquiatr Psicol Am Lat; 1986 Sep; 32(3):233-6. PubMed ID: 2884807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.